Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker
C, Martins V, Folkerd E, Clark J, Cooper
C, Kaye S, Dearnaley D,
Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71.
Eisenberger MA. Eur Urol. 2009 Jan; 55(1):248.